4/A: AN2 Therapeutics CEO Eric Easom Amends SEC Filing Regarding Stock Vesting Schedule
SEC Form 4/A Amendment
Eric Easom, CEO of AN2 Therapeutics, amends a previous SEC Form 4 filing to clarify the vesting schedule of restricted stock units.
Summary
- Eric Easom, the CEO of AN2 Therapeutics, filed an amendment to a previous Form 4 with the SEC.
- The amendment clarifies the vesting schedule for restricted stock units.
- The original filing was made on March 18, 2024, and the amended filing is dated March 29, 2024.
- The vesting schedule is 1/4th of the shares vests annually over four years from January 1, 2024, subject to continuous service.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, indicating standard corporate governance practices. The amendment clarifies details, which is a positive sign of transparency.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.
Comparison to Industry Standards
- Vesting schedules for restricted stock units are a common practice in the biotech industry to incentivize and retain key executives.
- Four-year vesting with annual installments is a standard vesting schedule observed across comparable companies.
Stakeholder Impact
- The clarification of the vesting schedule provides more transparency to shareholders regarding executive compensation.
- The vesting schedule incentivizes the CEO to remain with the company, which benefits stakeholders.
Key Dates
| Date | Description |
|---|---|
| 2023/12/13 | Date of Power of Attorney execution. |
| 2024/01/01 | Start date for the vesting schedule of restricted stock units. |
| 2024/03/15 | Date of the transaction involving common stock. |
| 2024/03/18 | Date of original Form 4 filing. |
| 2024/03/29 | Date of amended Form 4/A filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.